Daaso Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 6 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 128.11%
- Profit Growth 568.58%
- Ebitda 1348.16%
- Net Worth 1025.66%
- Total Assets 64.08%
About Daaso Pharmaceuticals
Daaso Pharmaceuticals Private Limited (DPPL) is a Private Limited Indian Non-Government Company incorporated in India on 27 February 2018 (Six years and 11 months 17 days old ). Its registered office is in Nagpur, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Sushil Bagde, Pallavi Wagh, and Deepak Gajghate serve as directors at the Company.
Company Details
-
Location
Nagpur, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U74999MH2018PTC305693
-
Company No.
305693
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
27 Feb 2018
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
What products or services does Daaso Pharmaceuticals Private Limited offer?
Daaso Pharmaceuticals Private Limited offers a wide range of products and services, including Protein Supplements, Amino Acids, Health Conditions, Mental Wellness.
Who are the key members and board of directors at Daaso Pharmaceuticals?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sushil Bagde
|
Director | 27-Feb-2018 | Current |
|
Pallavi Wagh
|
Director | 23-Nov-2019 | Current |
|
Deepak Gajghate
|
Director | 06-Jun-2022 | Current |
Financial Performance of Daaso Pharmaceuticals.
Daaso Pharmaceuticals Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 128.11% increase. The company also saw a substantial improvement in profitability, with a 568.58% increase in profit. The company's net worth Soared by an impressive increase of 1025.66%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Daaso Pharmaceuticals?
In 2019, Daaso Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Daaso Pharmaceuticals?
Unlock and access historical data on people associated with Daaso Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Daaso Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Daaso Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
